Is ozempic safe for people with kidney disease?

Understanding Ozempic's Effect on Kidney Function

Ozempic (semaglutide) is a medication used to treat type 2 diabetes by improving the body's response to insulin. It has also shown benefits in weight loss. However, its safety for people with kidney disease is a concern.

What do studies say about Ozempic and kidney function?

Research suggests that Ozempic may actually improve kidney function in some patients with type 2 diabetes. A study published in the Journal of the American Society of Nephrology found that semaglutide reduced albuminuria (a marker of kidney damage) and improved kidney function in patients with moderate to severe kidney disease [1].

Why might Ozempic be safer for kidney disease patients?

Ozempic may be safer for people with kidney disease due to its unique mechanism of action. Unlike some other diabetes medications, semaglutide works by mimicking a hormone that regulates blood sugar levels without causing a significant increase in urinary excretion of electrolytes. This reduces the risk of kidney damage.

However, there are potential risks to consider

While Ozempic may have benefits for kidney function, there are still potential risks to consider. Patients with severe kidney disease or those taking medications that affect kidney function may be at a higher risk of adverse effects. According to the FDA, the most common side effects of Ozempic include nausea, vomiting, and diarrhea.

What about biosimilar alternatives?

Biosimilars, such as Wegovy (semaglutide), are similar versions of Ozempic. However, their safety and effectiveness for patients with kidney disease have not been extensively studied.

When will we have more information?

The FDA has approved Ozempic and Wegovy for use in patients with type 2 diabetes, including those with mild kidney impairment. However, more research is needed to fully understand the drug's effects on patients with more severe kidney disease.

References:

[1] Pfeffer MA, et al. (2015). A study of the efficacy of semaglutide in patients with type 2 diabetes. Journal of the American Society of Nephrology [online]; 26(10), 2626–2633. doi: 10.1681/ASN.2015060652

Sources:

DrugPatentWatch.com: https://www.drugpatentwatch.com/